Tanabe Pharmaceutical has agreed to sell its domestic manufacturing subsidiary, Tanabe Pharma Factory, to Towa Pharmaceutical as part of a strategic shift towards research, development and business development.

• Asset Transfer: Towa Pharmaceutical will acquire Tanabe Pharma Factory, including the Onoda and Yoshitomi manufacturing plants, along with the manufacturing and marketing approvals, rights and related assets for 17 products across 35 specifications.
• Implementation Timeline: The share transfer is expected to be completed by the end of November 2026, with the transfer of manufacturing and marketing responsibilities beginning in phases from April 2027.
• Strategic Shift: The divestment supports Tanabe’s transition to a business model that no longer relies on owning primary manufacturing facilities, allowing the company to focus on research and development while maintaining stable product supply during the transition.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.